A

AOA

AI-enabled platform for early cancer detection

Senior Android Engineer

Full-TimeUpdated on 10/15/2026
$5k/mo
Senior
Remote in Brazil
RemoteMust be based in Latin America and overlap with standard US Central Time business hours.
Software EngineeringMobile Engineering

About the job

Requirements
  • At least 5 years of experience building production Android applications in Kotlin.
  • Deep, current expertise with the Android platform.
  • Hands-on experience building Android applications for custom, embedded, or non-phone hardware.
  • Experience integrating device hardware such as cameras, sensors, peripherals, or physical controls.
  • Experience designing offline-first or local-data architectures with future synchronization in mind.
  • Experience with Bluetooth, Wi-Fi, over-the-air updates, or device pairing.
  • A track record of owning Android architecture end-to-end as a senior engineer.
  • Strong judgment in resolving open technical decisions and owning tradeoffs.
  • Strong Android fundamentals, including lifecycle, state management, performance, and memory.
  • Experience taking ambiguous requirements through to production on real hardware.
  • A strong quality discipline, including typed, tested code and on-device verification before quality assurance.
  • Ability to estimate work, commit within a delivery cycle, and reliably deliver.
  • Professional English proficiency, spoken and written.
  • Strong written communication and proactive, independent work in a fully remote team.
  • Reliable overlap with standard US Central Time business hours.
  • Fluent, practical use of AI coding tools as part of an engineering workflow.
  • Must be based in Latin America and able to work as an independent contractor.
Responsibilities
  • Deliver high-quality, high-performing embedded Android experiences with predictable delivery, efficient use of AI agents, and collaborative ownership.
  • Own the end-to-end Android architecture for native Android on custom ARM-based embedded hardware.
  • Design an offline-first, modular system with local data architecture that can support future cloud synchronization.
  • Design encrypted per-profile storage, the local database, and build variants for the embedded device.
  • Resolve open architecture decisions and own the technical path forward.
  • Integrate device hardware into the app, including onboard cameras, controlled lighting, proximity sensors, and physical navigation controls.
  • Build shared hardware-abstraction layers for camera management, physical input, and device lifecycle behavior.
  • Design for display power states, cold boot, power transitions, abnormal shutdowns, and constrained hardware resources.
  • Build the on-device Kotlin experience from approved designs and specifications, including a user interface navigated by physical controls.
  • Ensure core product features work reliably offline.
  • Implement Bluetooth audio, Wi-Fi synchronization, over-the-air updates, offline device-to-device transfer, and casting or streaming.
  • Design connected-device flows to degrade gracefully without bricking the device or corrupting data.
  • Build and maintain companion mobile apps and device-to-companion integration, including pairing, transfer, and shared data contracts.
  • Meet device performance targets for cold boot, profile switching, and camera initialization.
  • Use the device GPU and NPU appropriately for imaging and augmented-reality work while managing memory and power limits.
  • Turn product-level requirements into clear engineering work and own the technical implementation approach.
  • Apply engineering and user-experience judgment beyond what is explicitly specified.
  • Write typed, tested, maintainable Kotlin that follows the existing codebase conventions.
  • Verify every feature on real hardware before handoff and catch issues before quality assurance.
  • Conduct code reviews and set the review standard for Android work.
  • Lead the Android work technically and raise the capability of the intermediate developer on the project.
  • Establish the patterns and abstractions that other Android work builds on.
  • Size work in points, commit within the monthly delivery cycle, and reliably deliver planned work.
  • Time-box investigative work to resolve genuine hardware unknowns before they become delivery risks.
  • Use AI coding tools and agents thoughtfully to increase throughput and quality while keeping engineering judgment in control of the final output.
  • Plan and sequence work across the device and companion-app surface.
  • Surface risks and tradeoffs early, and communicate proactively across a remote team.
Desired Qualifications
  • Platform- or operating-system-adjacent work, including Android Open Source Project-level engineering, native C/C++ via the Native Development Kit or Java Native Interface, or custom ROM or hardware abstraction layer work.
  • Multi-camera work with Camera2 or CameraX, on-device computer vision, or machine learning and augmented-reality work using the device GPU or NPU.
  • Bluetooth audio using A2DP or HFP, Matter, or Thread experience.
  • Experience building or operating an over-the-air update pipeline.
  • Companion app and device-pairing experience.
  • Mentoring or technical leadership of other engineers.
  • A portfolio, GitHub profile, or code samples that can be shared.

About the company

AOA Dx develops GlycoLocate™, an AI-powered platform for early cancer detection that uses tumor marker gangliosides as biomarkers. The system analyzes data from patients to identify cancer at its earliest stages, with a focus on women’s health. The company licenses its technology to healthcare providers and institutions, enabling them to enhance diagnostic capabilities and patient care. Unlike many competitors that rely on traditional biomarkers or slower workflows, GlycoLocate™ combines data science with a novel class of biomarkers (glycolipids) to offer actionable early-detection insights. The goal is to deliver cost-effective, scalable cancer-detection technology that can be integrated into existing clinical workflows, advancing preventative care and improving outcomes.

Company Size

51-200

Company Stage

Early VC

Total Funding

$29.1M

Headquarters

Denver, Colorado

Founded

2019

Get referred to AOA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AOA Dx enrolled its first OVERT patient in May 2026, accelerating clinical validation.
  • June 2026 ASCO data reported 92% stage I/II sensitivity, strengthening investor and partner confidence.
  • The 2023 and 2026 seed financing, totaling $24 million, funds trials and lab expansion.

What critics are saying

  • Commercial launch still depends on OVERT and APEX clinical execution through 2026.
  • Competing ovarian diagnostics from CA125-adjacent incumbents and liquid-biopsy startups can commoditize claims fast.
  • Failure to secure regulatory clearance or reimbursement by 2027 traps AOA Dx in perpetual research.

What makes AOA unique

  • AOA Dx’s AKRIVIS GD targets symptomatic ovarian cancer, a neglected diagnostic gap.
  • Its multi-omic platform combines gangliosides, lipids, metabolites, proteins, and machine learning.
  • 2026 AACR data showed independent-cohort AUC 0.92, validating reproducible assay performance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-1%
Intelligence360 News
Oct 28th, 2025
AOA DX Inc. Raises $30.6M Funding

AOA DX Inc. has filed a notice with the SEC for an exempt offering of securities to raise up to $30.6 million. This filing is required under federal securities law for companies selling securities without registration under specific exemptions. The notice must be filed within 15 days of the first sale. AOA DX is focused on early-stage cancer detection for women using AI and proprietary biomarker technology.

Femtech Insider
May 5th, 2025
AOA Dx Reports High Accuracy for AI-Powered Ovarian Cancer Blood Test in 1,000 Patient Study

AOA Dx, a company developing blood-based diagnostics for early cancer detection, has demonstrated high accuracy in detecting ovarian cancer in symptomatic women using its AI-powered multi-omic platform, according to data presented at the 2025 American Association for Cancer Research Annual Meeting.

PR Newswire
Jul 31st, 2024
Colorado Bioscience Association Highlights Investment Opportunities At The 2024 Rocky Mountain Life Sciences Investor Partnering Conference

Presenting Companies Represent Transformative Technologies from the Rocky Mountain WestDENVER, July 31, 2024 /PRNewswire/ -- Colorado BioScience Association (CBSA) highlights the momentum and opportunities in Colorado's life sciences community and the greater Rocky Mountain region at the 2024 Rocky Mountain Life Sciences Investor & Partnering Conference in Breckenridge, Colorado, on September 12 and 13.Colorado BioScience AssociationThe conference aims to drive more commercialization and patient impact by attracting new funding and strategic partnerships in a region recognized as a leading hub for health innovation. CNBC covered record fundraising by Colorado's life sciences ecosystem earlier this year. In the first six months of 2024, life sciences companies and organizations raised more than $1.2 billion. Additionally, Colorado Hub for Health Impact, a national economic development campaign led by a collaboration of 22 partners, is attracting new life sciences companies, talent, and investors to Colorado.Known for its exclusive focus on life sciences, the conference will feature more than 30 pre-selected startup, emerging, and growth companies. Presenting companies are developing transformative devices, diagnostics and therapies. They are tackling cancers, drug-resistant diseases, autoimmune conditions, and women's health disparities using some of the most promising technological advancements in artificial intelligence, regenerative and personalized medicine, and synthetic biology."Colorado BioScience Association encourages investors and strategic partners to join us at the 2024 Rocky Mountain Life Sciences Investor & Partnering Conference and seize opportunities to invest in and partner with pioneering Colorado life sciences companies," said Elyse Blazevich, Colorado BioScience Association President & CEO

BioWorld
Oct 12th, 2023
AOA nabs $17M for ovarian cancer diagnostic trial expansion

AOA Dx Inc. closed an oversubscribed $17 million seed round to expand the clinical trial for its ovarian cancer diagnostic test, build out new lab facilities and explore applications of its Glycolocate platform in other cancers.

CIF Impact
Sep 11th, 2023
Portfolio Companies — Catalytic Impact Foundation

Our portfolio consists of companies addressing health equity, aging, cancer research, women's health, rare and neglected diseases and more. We operate similar to a traditional venture capital firm making equity investments in promising medical innovations.